All In Biotech

NDA 215000 · Accord Hlthcare

Carmustine

Carmustine · Intravenous

Discontinued

Last checked: Nov 20, 2026Latest source record: May 16, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

May 16, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

259

44 Phase 3, 18 recruiting

FAERS reports

4,156

4,089 serious, 1,117 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • CARMUSTINE · CARMUSTINE 50MG/VIAL · POWDER, INTRAVENOUS · Discontinued
  • CARMUSTINE · CARMUSTINE 300MG/VIAL · POWDER, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Carmustine" as an intervention, any sponsor and status, largest first.

All 259 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use510
  • febrile neutropenia400
  • myelodysplastic syndrome298
  • disease progression269
  • mucosal inflammation256
  • thrombocytopenia232
  • pyrexia209
  • neutropenia206
  • pneumonia199
  • drug ineffective197
  • acute myeloid leukaemia172
  • infection165

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200484
200554
200635
200773
200898
200992
201069
2011132
2012128
201384
201461
2015132
2016102
2017223
2018315
2019336
2020367
2021309
2022280
2023432
2024293
2025229
2026228

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 434 on PubMed

Sponsor: Accord Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.